FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing

Five Star Equities Provides Stock Research on Idenix Pharmaceuticals and Peregrine Pharmaceuticals

Marketwired

NEW YORK, NY--(Marketwire - Mar 11, 2013) - Programs developed by the U.S. Food and Drug Administration to speed up the approval process has been a major driver for growth within the Biotech Industry. In 2012, FDA drug approvals totaled a 15-year high of 39, over the past decade drug approvals has averaged roughly 23 a year, according to a recent Bloomberg article. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Peregrine Pharmaceuticals (NASDAQ: PPHM).

Access to the full company reports can be found at:

www.FiveStarEquities.com/IDIX

www.FiveStarEquities.com/PPHM

The FDA's new "breakthrough" product designation allows new drugs to win approval after just a single round of testing, instead of the usual three. A total of three promising experimental medicines have been assigned the new status so far, while an additional 18 drugs have applied. The new designation follows three other programs -- Fast Track, Priority Review and Accelerated Approval -- each of which were designed to help bring crucial new drugs to market in a shorter amount of time.

"A breakthrough drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Idenix's current focus is on the treatment of hepatitis C virus (HCV) infections. The company has previously discovered and developed antivirals for the treatment of hepatitis B virus (HBV) and HIV/AIDS. The company reported revenues of $69.7 million for the full year 2012, compared to revenues of $7 million a year ago.

Peregrine Pharmaceuticals patented monoclonal antibodies target various physical structures common to tumors or infected cells as a means to selectively target therapy and diagnostics, while sparing normal, healthy cells. Their most advanced research focus is on the development of therapeutic antibodies that specifically target and act upon features of cancer and viral infections, including the blood vessels feeding tumors, distinctive features in the central core of tumors and cells that have been infected with viruses.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

Rates

View Comments (1)